{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["McNally CJ"],"pubmed_abstract":["<h4>Background</h4>Almost 50,000 men in the United Kingdom (UK) are diagnosed each year with prostate cancer (PCa). Secondary referrals for investigations rely on serum prostate-specific antigen (PSA) levels and digital rectal examination. However, both tests lack sensitivity and specificity, resulting in unnecessary referrals to secondary care for costly and invasive biopsies.<h4>Materials and methods</h4>Serum samples and clinical information were collected from <i>N</i> = 125 age-matched patients (<i>n</i> = 61 non-PCa and <i>n</i> = 64 PCa) and analyzed using Biochip Array Technology on high-sensitivity cytokine array I (IL-2, IL-4, IL-6, IL-8, IL-10, IL-1α, IL-1β, TNFα, MCP-1, INFγ, EGF, and VEGF), cerebral array II (CRP, D-dimer, neuron-specific enolase, and sTNFR1), and tumor PSA on"],"journal":["Frontiers in oncology"],"pagination":["837127"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9161691"],"repository":["biostudies-literature"],"pubmed_title":["A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into \"Low-\" and \"High-Risk\" Categories for Prostate Cancer."],"pmcid":["PMC9161691"],"pubmed_authors":["Watt J","Lamont JV","Pandha H","Ruddock MW","Fitzgerald P","McNally CJ","Kurth MJ","McKenna DJ","Moore T"],"additional_accession":[]},"is_claimable":false,"name":"A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into \"Low-\" and \"High-Risk\" Categories for Prostate Cancer.","description":"<h4>Background</h4>Almost 50,000 men in the United Kingdom (UK) are diagnosed each year with prostate cancer (PCa). Secondary referrals for investigations rely on serum prostate-specific antigen (PSA) levels and digital rectal examination. However, both tests lack sensitivity and specificity, resulting in unnecessary referrals to secondary care for costly and invasive biopsies.<h4>Materials and methods</h4>Serum samples and clinical information were collected from <i>N</i> = 125 age-matched patients (<i>n</i> = 61 non-PCa and <i>n</i> = 64 PCa) and analyzed using Biochip Array Technology on high-sensitivity cytokine array I (IL-2, IL-4, IL-6, IL-8, IL-10, IL-1α, IL-1β, TNFα, MCP-1, INFγ, EGF, and VEGF), cerebral array II (CRP, D-dimer, neuron-specific enolase, and sTNFR1), and tumor PSA on","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T13:18:25.931Z","creation":"2024-11-09T08:40:58.293Z"},"accession":"S-EPMC9161691","cross_references":{"pubmed":["35664747"],"doi":["10.3389/fonc.2022.837127"]}}